Europe Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, and Others), Nature (Human and Humanized, Chimeric, and Murine), Services (Phage Display, Hybridoma, Transgenic Animal,

Europe Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, and Others), Nature (Human and Humanized, Chimeric, and Murine), Services (Phage Display, Hybridoma, Transgenic Animal, Single Cell, and Yeast Display), and End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, and Others)

The Europe antibody discovery market was valued at US$ 8,24,441.11 million in 2022 and is expected to reach US$ 13,29,481.60 million by 2030; it is estimated to register a CAGR of 6.2% from 2022 to 2030.

Rising Incidence of Cancer Drives Europe Antibody Discovery Market

As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the world. By January 2030, the population of cancer survivors is estimated to reach 22.1 million, which can be primarily associated with the aging of the population. Lung, breast, colorectal, prostate, and breast are among the most commonly reported cancer types. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020.

New Cancer Cases Worldwide, in 2020
Sr. No.
Cancer Type
Number of Cases (Million)
1
Stomach
1.09
2
Skin (non-melanoma)
1.2
3
Prostate
1.41
4
Colon and rectum
1.93
5
Lung
2.21
6
Breast
2.26
Source: World Health Organization, February 2020

Cancer is now a lifestyle disease commonly seen among people with unhealthy eating habits and those who don’t engage much in physical activities. The frequent consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody–drug conjugates (ADCs) have also shown promising results in cancer treatment. Further, progress in modern biotechnology allows researchers and companies to provide well-designed novel antibodies, paving the way for successful treatments of various types of cancer. Thus, the burgeoning incidence of different types of cancer boosts the antibody discovery market growth.

Europe Antibody Discovery Market Overview

The European antibody discovery market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global market. It is expected to register a robust growth rate in the coming years owing to the surging use of monoclonal antibodies in R&D applications, cancer therapies, and immunological disorder management. Further, the rising need for patient data management systems, the prevalence of chronic diseases, and government initiatives for the implementation of antibody services are expected to provide growth opportunities for the antibody discovery market in countries such as France, Italy, and Spain.

Europe Antibody Discovery Market Revenue and Forecast to 2030 (US$ Billion)

Europe Antibody Discovery Market Segmentation

The Europe antibody discovery market is categorized into antibody type, nature, services, end user, and country.

Based on antibody type, the Europe antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held the largest Europe antibody discovery market share in 2022.

In terms of nature, the Europe antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held the largest Europe antibody discovery market share in 2022.

By services, the Europe antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held the largest Europe antibody discovery market share in 2022.

Based on end user, the Europe antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held the largest Europe antibody discovery market share in 2022.

Based on country, the Europe antibody discovery market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe antibody discovery market share in 2022.

Charles River Laboratories International Inc, Creative Biolabs Inc, Evotec SE, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, and Biocytogen Pharmaceuticals Beijing Co Ltd. are some of the leading companies operating in the Europe antibody discovery market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe antibody discovery market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe antibody discovery market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe antibody discovery market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.